Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Result of AGM

31 Jan 2012 15:24

RNS Number : 5120W
CareCapital Group plc
31 January 2012
 



31 January 2012

 

CARECAPITAL GROUP PLC

("CareCapital" or "the Company")

 

Result of Annual General Meeting

 

CareCapital plc (AIM: CARE) announces that at the Company's Annual General Meeting held today all resolutions were duly passed. The resolutions passed were:

 

Ordinary Business

1. To receive the report of the directors, the auditor's report and the audited financial statements for the period ended 31 December 2010.

 

2. To re-appoint Paul Quentin Cullum Stacey as a director of the Company who retires in accordance with the Company's Articles of Association and who, being eligible, offers himself for re-appointment.

 

3. To re-appoint Donald Baladasan as a director of the Company who retires in accordance with the

Company's Articles of Association and who, being eligible, offers himself for re-appointment.

 

4. To re-appoint PKF (UK) LLP as auditors of the Company to hold office from the conclusion of this meeting until the conclusion of the next general meeting at which accounts are laid before the Company.

 

5. To authorise the Directors to determine the remuneration of the auditors.

 

Special Business

6. That the articles of association produced to the meeting and initialled by the Chairman of the meeting for the purposes of identification (the "Articles of Association") be and are hereby adopted as the articles of association of the Company in substitution for and to the exclusion of the Company's existing articles of association.

 

7. That the existing memorandum of association of the Company be amended by the deletion of paragraphs 4.1, 4.2 and 6.

 

8. THAT the Directors be and are hereby generally and unconditionally authorised for the purposes of section 551 of the Companies Act 2006 ("the Act"), to exercise all the powers of the Company to allot shares in the Company and/or to grant rights to subscribe for, or to convert any securities into, shares in the Company, provided that such authority shall be limited to the allotment of Ordinary Shares of £0.01 each in the capital of the Company ("Ordinary Shares") and/or the grant of rights to subscribe for or to convert any securities into Ordinary Shares up to an aggregate nominal amount of £1,406,005 (the equivalent of up to 140,600,500 Ordinary Shares), this authority to expire on the earlier of fifteen months from the date of the passing of this resolution or the conclusion of the next Annual General Meeting of the Company to be held in 2012 unless previously renewed, varied or revoked by the Company in general meeting, save that the Company may before such expiry make any offer or agreement which would or might require shares in the Company to be allotted and/or rights to subscribe for or to convert any securities into shares in the Company to be granted after such expiry and the Directors may allot shares in the Company, or grant rights to subscribe for or to convert any securities into shares in the Company, in pursuance of any such offer or agreement as if the authority conferred hereby had not expired.

 

9. THAT, subject to the passing of Resolution 8 above, in substitution for all previous powers to the extent unused, the Directors be and are hereby unconditionally empowered pursuant to sections 570 and 571 of the Act to allot equity securities (as defined in section 560 of the Act) pursuant to the authority granted to the Directors pursuant to Resolution 8 above as if section 561 of the Act did not apply to any such allotment, provided that this power shall be limited to:

 

9.1 the allotment of equity securities in connection with a rights issue, open offer or equivalent offer in favour of the holders of Ordinary Shares and such other equity securities of the Company as the Directors may determine in which such holders are offered the right to participate in proportion (as nearly as may be) to their respective holdings of such equity securities or in accordance with the rights attached thereto but subject to such exclusions or other arrangements as the Directors may consider necessary or expedient in connection with shares representing fractional entitlements or on account of either legal or practical problems arising in connection with the laws of any territory, or of the requirements of any recognised regulatory body or stock exchange in any territory;

 

9.2 other than pursuant to sub-paragraph 9.1 above, the allotment of equity securities up to an aggregate nominal amount of £1,406,005 (the equivalent of up to 140,600,500 Ordinary Shares),

 

and this power shall expire on the earlier of fifteen months from the date of passing of this resolution and upon the conclusion of the next Annual General Meeting of the Company to be held in 2012 unless previously renewed, varied or revoked by the Company in general meeting, save that the Company may before such expiry make any offer or agreement which would or might require equity securities to be allotted after such expiry and the Directors may allot equity securities in pursuance of any such offer or agreement as if the power conferred hereby had not expired.

 

-ends-

 

For further information, please visit www.carecapital.co.uk or contact:

 

Mike Sinclair, Chairman

Paul Stacey, Managing Director

Sandy Jamieson

Jon Levinson

Simon Hudson,

 

CareCapital Group PlcLibertas Partners LLPRivington Street

Corporate Finance

Tavistock Communications
 (NOMAD &Joint Broker)

(Joint Broker)

(Financial PR & IR)

020 7034 1949020 7569 9650

020 7562 3357

020 7920 3150

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGBKDDBPBKDBDN
Date   Source Headline
9th May 20247:00 amRNSCancellation - Advanced Oncotherapy Plc
3rd May 20248:54 amRNSFurther update on financing discussions
2nd Apr 20243:50 pmRNSFurther update on financing discussions
29th Feb 20245:19 pmRNSFurther update on financing discussions
1st Feb 20247:00 amRNSFurther update on financing discussions
9th Jan 20249:00 amRNSUpdate on Financing Discussions
23rd Oct 20237:00 amRNSUpdate on Financing and Current Financial Position
17th Jul 20237:00 amRNSRecapitalisation and funding plan, update on FSP
30th Jun 20235:00 pmRNSTotal Voting Rights
30th Jun 20237:30 amRNSSuspension - Advanced Oncotherapy PLC
30th Jun 20237:15 amRNSUpdate on financing, suspension of trading on AIM
29th Jun 20231:35 pmRNSHolding(s) in Company
29th Jun 20239:59 amRNSForm 8.3 - Advanced Oncotherapy PLC
28th Jun 202310:25 amRNSForm 8.3 - Advanced Oncotherapy PLC
27th Jun 202310:29 amRNSForm 8.3 - Advanced Oncotherapy
27th Jun 202310:25 amRNSForm 8.3 - Advanced Oncotherapy
26th Jun 20234:26 pmRNSForm 8.3 - Advanced Oncotherapy
26th Jun 202310:57 amRNSPartial conversion of Convertible Notes
23rd Jun 202311:05 amRNSHolding(s) in Company
23rd Jun 20239:30 amRNSForm 8.3 - Advanced Oncotherapy PLC
20th Jun 20235:28 pmRNSHolding(s) in Company
19th Jun 20235:56 pmRNSPartial conversion of Convertible Notes
19th Jun 20231:48 pmRNSForm 8.3 - Advanced Oncotherapy PLC
16th Jun 20236:23 pmRNSIssue of warrants
13th Jun 202311:46 amRNSForm 8.3 - Advanced Oncotherapy PLC
31st May 20235:57 pmRNSUpdate on financing and convertible notes
30th May 202310:42 amRNSForm 8.3 - Advanced Oncotherapy Plc
24th May 20235:54 pmRNSForm 8 (OPD) Advanced Oncotherapy plc
24th May 20235:29 pmRNSForm 8.3 - Advanced Oncotherapy - Cosylab d.d.
22nd May 20232:59 pmRNSForm 8.3 - Advanced Oncotherapy plc
19th May 202312:09 pmRNSForm 8.3 - Advanced Oncotherapy PLC
17th May 20232:58 pmRNSForm 8.3 - Advanced Oncotherapy plc
15th May 202311:36 amRNSUpdate on Convertible Note & Loan Extension
15th May 20239:19 amRNSForm 8.3 - Advanced Oncotherapy Plc
12th May 202312:53 pmRNSForm 8.3 - Advanced Oncotherapy - Minmetco Limited
11th May 20235:14 pmRNSForm 8.3 - Advanced Oncotherapy - eQ Blue Planet
11th May 202311:17 amRNSForm 8.3 - Advanced Oncotherapy - Atlantic Cedar
10th May 202311:34 amRNSForm 8.3 - Advanced Oncotherapy plc
9th May 20234:40 pmRNSForm 8.3 - Advanced Oncotherapy - Baltisches Haus
9th May 20234:37 pmRNSForm 8.3 - Advanced Oncotherapy plc
9th May 20234:36 pmRNSForm 8.3 - Advanced Oncotherapy plc
5th May 20238:56 amRNSFORM 8.3 - Advanced Oncotherapy
5th May 20237:00 amRNSAdditional funding from Secured Convertible Note
4th May 20235:01 pmRNSForm 8.3 - Advanced Oncotherapy Plc
4th May 20233:55 pmRNSChange of Registered Office
3rd May 20236:19 pmRNSRule 2.9 Announcement
3rd May 20234:28 pmRNSForm 8.3 - Advanced Oncotherapy PLC
2nd May 20236:19 pmRNSForm 8 (OPD) Advanced Oncotherapy plc
18th Apr 20237:00 amRNSStrategic review and formal sale process
31st Mar 20236:05 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.